X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 59 filers reported holding X4 PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 3.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $532,000 | +77.3% | 311,490 | 0.0% | 1.65% | +140.6% |
| Q2 2022 | $300,000 | -45.0% | 311,490 | 0.0% | 0.68% | +4.1% |
| Q1 2022 | $545,000 | -23.6% | 311,490 | 0.0% | 0.66% | +42.7% |
| Q4 2021 | $713,000 | -56.7% | 311,490 | 0.0% | 0.46% | -42.8% |
| Q3 2021 | $1,648,000 | -18.6% | 311,490 | 0.0% | 0.81% | -8.6% |
| Q2 2021 | $2,025,000 | -24.5% | 311,490 | 0.0% | 0.88% | -12.2% |
| Q1 2021 | $2,682,000 | +33.9% | 311,490 | 0.0% | 1.00% | +4.1% |
| Q4 2020 | $2,003,000 | -5.0% | 311,490 | 0.0% | 0.96% | -9.7% |
| Q3 2020 | $2,109,000 | -27.4% | 311,490 | 0.0% | 1.07% | -46.9% |
| Q2 2020 | $2,904,000 | -6.8% | 311,490 | 0.0% | 2.01% | -22.9% |
| Q1 2020 | $3,115,000 | -6.5% | 311,490 | 0.0% | 2.61% | +29.4% |
| Q4 2019 | $3,333,000 | -15.8% | 311,490 | 0.0% | 2.02% | -27.3% |
| Q3 2019 | $3,957,000 | -15.3% | 311,490 | 0.0% | 2.78% | -11.4% |
| Q2 2019 | $4,672,000 | -13.8% | 311,490 | 0.0% | 3.14% | -1.4% |
| Q1 2019 | $5,423,000 | – | 311,490 | – | 3.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,682,000 | 3.48% |
| Sio Capital Management, LLC | 804,597 | $6,928,000 | 1.41% |
| Bain Capital Life Sciences Investors, LLC | 2,119,540 | $18,249,000 | 1.03% |
| SV Health Investors, LLC | 311,490 | $2,682,000 | 1.00% |
| Monashee Investment Management LLC | 574,712 | $4,948,000 | 0.76% |
| Ikarian Capital, LLC | 2,614,988 | $22,515,000 | 0.76% |
| Abingworth LLP | 229,885 | $1,956,000 | 0.68% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,884,000 | 0.67% |
| BVF INC/IL | 1,091,579 | $9,398,000 | 0.35% |
| Endurant Capital Management LP | 151,996 | $1,309,000 | 0.34% |